Press Releases
May 26, 2022
CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors
Additional Formats
May 5, 2022
CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Additional Formats
April 28, 2022
CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022
Additional Formats
April 14, 2022
CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors
Additional Formats
March 23, 2022
CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors
Additional Formats
March 17, 2022
CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022
Additional Formats
March 1, 2022
CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update
Additional Formats
February 28, 2022
CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference
Additional Formats
February 22, 2022
CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
Additional Formats
February 16, 2022
CytomX Therapeutics Announces New Employment Inducement Grants
Additional Formats
Displaying 1 - 10 of 14